Targeting CD147 is a Novel Strategy for Antitumor Therapy

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Cluster of Differentiation 147 (CD147), also known as extracellular matrix metalloproteinase inducer (EMMPRIN), is an immunoglobulin superfamily member expressed on the cell membrane.
• CD147's role in inducing matrix metalloproteinases (MMPs) facilitates tumor cell migration and invasion.
• Overexpression of CD147 is observed in various cancers, including melanoma, liver, and lung cancer.

Purpose of the Study:

• To review the biological functions of CD147 in physiological and pathological processes.
• To highlight CD147's involvement in critical cancer hallmarks such as proliferation, apoptosis, invasion, metastasis, multidrug resistance, and glycolysis.
• To explore CD147's potential as a diagnostic marker and therapeutic target in oncology.

Main Methods:

• Literature review of recent studies on CD147.
• Analysis of CD147's interactions with key molecules like MMPs, MCTs, Caveolin-1, and VEGF.
• Examination of CD147's role in cancer progression and therapeutic strategies.

Main Results:

• CD147 orchestrates tumor cell proliferation, apoptosis, invasion, metastasis, multidrug resistance, and glycolysis.
• CD147 influences cancer progression through interactions with MMPs, MCTs, Caveolin-1, and VEGF.
• Accumulating evidence supports CD147's significant role in the development and progression of various cancers.

Conclusions:

• CD147 is a crucial molecule implicated in multiple facets of cancer biology.
• CD147 demonstrates potential as a valuable diagnostic biomarker for cancer.
• Targeting CD147 offers a promising therapeutic strategy for cancer treatment and diagnosis.